Capsida Biotherapeutics
Biotechnology, 290 Rancho Conejo BLVD, Newbury Park, California, 91320, United States, 51-200 Employees
Phone Number: 18*********
Who is CAPSIDA BIOTHERAPEUTICS
Capsida Biotherapeutics Inc. is an industry-leading gene therapy platform company creating a new class of targeted, non-invasive gene therapies for patients with debilitating and life-thr...
Read More
-
Headquarters: 290 Rancho Conejo BLVD, Newbury Park, California, 91320, United States
-
Date Founded: 2019
-
Employees: 51-200
-
Revenue: $1 Million to $5 Million
-
Active Tech Stack: See technologies
Industry: Biotechnology
SIC Code: 38
|
NAICS Code: 33 |
Show More
Does something look wrong? Fix it. | View contact records from CAPSIDA BIOTHERAPEUTICS
Capsida Biotherapeutics Org Chart and Mapping
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Capsida Biotherapeutics
Answer: Capsida Biotherapeutics's headquarters are located at 290 Rancho Conejo BLVD, Newbury Park, California, 91320, United States
Answer: Capsida Biotherapeutics's phone number is 18*********
Answer: Capsida Biotherapeutics's official website is https://capsida.com
Answer: Capsida Biotherapeutics's revenue is $1 Million to $5 Million
Answer: Capsida Biotherapeutics's SIC: 38
Answer: Capsida Biotherapeutics's NAICS: 33
Answer: Capsida Biotherapeutics has 51-200 employees
Answer: Capsida Biotherapeutics is in Biotechnology
Answer: Capsida Biotherapeutics contact info: Phone number: 18********* Website: https://capsida.com
Answer: Capsida Biotherapeutics Inc. is an industry-leading gene therapy platform company creating a new class of targeted, non-invasive gene therapies for patients with debilitating and life-threatening genetic disorders. Capsida's technology allows for the targeted penetration of cells and organs, while limiting collateral impact on non-targeted cells and organs, especially the liver. This technology allows for the delivery of the gene therapy in a non-invasive way through intravenous administration. Capsida's technology is protected by a growing intellectual property portfolio which includes more than 30 patent applications and one issued U.S. patent 11,149,256. The company is exploring using the technology across a broad range of life-threatening genetic disorders. Its initial pipeline consists of multiple neurologic disease programs. The company has strategic collaborations with AbbVie and CRISPR, which provide independent validation of Capsida's technology and capabilities. Capsida is a multi-functional and fully integrated biotechnology company with proprietary adeno-associated virus (AAV) engineering, multi-modality cargo development and optimization, translational biology, process development and state-of-the-art manufacturing, and broad clinical development experience. Capsida's biologically driven, high-throughput AAV engineering and cargo optimization platform originated from groundbreaking research in the laboratory of Viviana Gradinaru, Ph.D., a neuroscience professor at the California Institute of Technology.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month